Table 3 Proposed charting form
From: Protocol for a scoping review to map patient engagement in scoping reviews
Category | Variable |
|---|---|
Publication characteristics | Title |
Year of publication | |
Journal (or source if unpublished) | |
Published (yes/no) | |
Author characteristics | Surnames |
Corresponding author contact information | |
Countries | |
Discipline; point of view; “lens” | |
Study characteristics | Health topic |
Design | |
Primary outcome(s) | |
Outcome measures | |
Type of health research (e.g., basic science, clinical, epidemiology) | |
Limitations/risk of bias | |
Stakeholder (i.e., patient or caregiver) characteristics | Who was engaged in the scoping review (patients, caregivers, both, other)? |
Total number of stakeholders engaged | |
What perspectives did the stakeholders represent? | |
Average stakeholder age | |
Stakeholder ethnicity/race | |
Stakeholder gender | |
Describe any other information provided about the stakeholders that was unrelated to their identity as a patient or caregiver. | |
During which Arksey and O’Malley scoping review stages were stakeholders engaged (i.e., 1–6, N/A, unclear)? | |
How were they stakeholders engaged (method of engagement)? | |
Consultation/engagement characteristics | What level along Manafo et al.’s [10] revised engagement spectrum best describes the engagement approach taken and why? Please indicate whether this was your perception vs. stated by the study authors. |
What was the established purpose of engaging stakeholders? | |
How did researchers keep track of stakeholder contributions (e.g., notes)? | |
How were stakeholder contributions incorporated and/or analyzed (e.g., thematic analysis, revision of preliminary framework)? | |
How did stakeholder contributions influence/impact the research and how was this measured? | |
Describe any strengths and limitations mentioned relevant to the engagement approach or process | |
What challenges to engagement were reported (if any)? | |
Which patient engagement reporting guideline was used, if any (e.g., GRIPP-2)? | |
Were stakeholders compensated (and if so, how)? | |
Were stakeholders co-authors of the review? | |
Please list any other information that you feel is relevant to note about this study’s engagement approach. |